GILEAD SCIENCES Business Summary

Gilead Sciences, Inc. (GILD) is a research-based biopharmaceutical company that generates revenue primarily through the global sale of prescription medicines to wholesalers, pharmacies, and healthcare providers. As of February 2026, the company’s business model is anchored by four primary segments: HIV and Virology, which remains its core revenue engine (led by Biktarvy and the long-acting injectable Sunlenca); Oncology, focused on antibody-drug conjugates like Trodelvy; Cell Therapy, operated through its Kite Pharma subsidiary (Yescarta and Tecartus); and Liver Disease, which includes treatments for HCV, HBV, and primary biliary cholangitis. Gilead maintains a dominant market position in the HIV space with approximately 70% market share, though it faces intense competition from ViiV Healthcare (a GSK joint venture), Merck & Co., and Bristol-Myers Squibb in oncology and cell therapy. The company is currently transitioning toward a more diversified portfolio, with 2026 revenue guidance projected between $29.6 billion and $30.0 billion. Originally founded in 1987 by Michael L. Riordan, Gilead is currently led by Chairman and CEO Daniel O’Day, a veteran of Roche who has spearheaded over $40 billion in strategic acquisitions to pivot the company toward oncology. The executive team includes CFO Andrew Dickinson, who oversees the firm’s robust capital allocation strategy, and Chief Medical Officer Dietmar Berger, MD, PhD, who joined in early 2025 to lead global clinical development. Technical and research leadership is provided by Flavius Martin, MD (EVP, Research) and Stacey Ma, PhD (EVP, Pharmaceutical Development and Manufacturing), both of whom bring extensive pedigrees from Amgen and Genentech. The company is backed by high institutional ownership (~84%), with a board of directors featuring prominent figures such as Lead Independent Director Anthony Welters and former Cisco CFO Kelly Kramer, providing deep expertise in both healthcare policy and operational scaling.